Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease

Fig. 3

Revised ESA Decision Aid. The revised ESA decision aid contains 6 sections organized to be delivered to patients from top to bottom. Section 1 explains the mechanism for how and why ESAs are used to treat anemia in kidney disease patients. Section 2 raises patient awareness of their current hemoglobin level and encourages them to set a new goal hemoglobin level with their providers. Section 3 presents the benefits of ESAs, while Section 4 presents the risks. Section 5 contains additional information to help patients understand the impact of their decision to use ESAs on downstream treatment options related to broader kidney health outcomes. Section 6 includes checkboxes to assist patients with planning their future ESA use

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us